HIV-related hematological malignancies: a concise review

Area of Science:

• Immunology
• Oncology
• Infectious Diseases

Background:

• Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) significantly impact immune function, increasing susceptibility to infections and cancers.
• The advent of Highly Active Antiretroviral Therapy (HAART) in 1996 has dramatically improved HIV patient outcomes, altering the spectrum of associated malignancies.
• While HAART has reduced certain HIV-related cancers like Kaposi's sarcoma, hematological malignancies persist as a major cause of mortality.

Purpose of the Study:

• To review the natural history of HIV disease concerning malignancy development.
• To emphasize the management and treatment of HIV-related hematological malignancies.
• To discuss the evolving landscape of cancers in HIV-infected individuals post-HAART.

Main Methods:

• Literature review focusing on HIV disease progression and oncogenesis.
• Analysis of changes in malignancy incidence and mortality pre- and post-HAART.
• Synthesis of current knowledge on HIV-associated hematological malignancies.

Main Results:

• HAART has led to a decrease in Kaposi's sarcoma and Primary CNS lymphomas in developed nations.
• Hematological malignancies, especially non-Hodgkin lymphomas, are now the most frequent cancer-related cause of death in HIV-infected individuals.
• Significant improvements in morbidity, mortality, and life expectancy are observed in HIV patients on HAART.

Conclusions:

• HIV/AIDS management has shifted the burden of cancer towards hematological malignancies.
• Effective treatment and management strategies for HIV-related hematological malignancies are crucial.
• Continued research into the pathogenesis and treatment of these cancers in the context of HIV is warranted.